Samyang Foods spent ₩449.0 billion on property, plant and equipment in 2025. Two years earlier the same line was ₩45.0 billion. The company that makes Buldak, the chilli ramen that walked out of Korean social media onto American grocery shelves, has turned into a capital-intensive manufacturer in about 24 months.
Samyang Foods Inc. (KRX:003230) is spending that money in two directions at once. One is more Korean capacity to feed exports. The other is a ₩201.4 billion plant in Jiaxing, in China's Zhejiang province, that will make up to 840 million units of Buldak a year for Chinese shoppers only. The plant is scheduled to open in January 2027.
That second decision is the one worth arguing about. The demand story so far has been Western. Samyang has led the growth of Korean ramen in the United States, and overseas sales were 83.8% of the June quarter. Yet the first factory the company has ever built outside Korea points at a market it has not yet won.
The step change is visible in the balance sheet, not just the cash flow statement. Property, plant and equipment stood at ₩475.3 billion at the end of 2022. At June 30, 2026 it was ₩1,157.7 billion. That is 2.4 times in three and a half years.
Capex by year tells the same story faster. It was ₩45.0 billion in 2023, ₩228.5 billion in 2024 and ₩449.0 billion in 2025. The first half of 2026 added another ₩103.3 billion, which looks like a pause rather than a stop. A single quarter, the second of 2025, carried ₩273.3 billion of it.
None of this is unreasonable for a company whose revenue went from ₩1,192.9 billion in 2023 to ₩2,351.8 billion in 2025. Capacity had to come from somewhere. What changed is the kind of company this is. A brand that ran asset-light for years is now signing off on plants with delivery dates in 2027.
2025 was the strongest year in Samyang's history. Operating income reached ₩524.2 billion. Net income was ₩388.7 billion.
Cash from operations was ₩309.3 billion. Subtract the ₩449.0 billion of capex and free cash flow was negative ₩139.7 billion.
Financing activities brought in ₩170.2 billion that year, so the shortfall was funded rather than absorbed. Total liabilities have kept climbing since, from ₩766.7 billion at the end of 2024 to ₩1,200.4 billion at the end of June. Cash also climbed, from ₩332.8 billion to ₩630.6 billion, and the June quarter alone drew ₩139.9 billion in from financing. A company raising money while holding ₩630.6 billion of cash is a company that knows what it still has to pay for.
Operating cash conversion has been lumpy in a way the income statement hides. In the June quarter, operating income was ₩176.2 billion but cash from operations was only ₩56.9 billion. Working capital took the difference. Trade receivables reached ₩256.4 billion against ₩140.6 billion a year earlier, an 82% rise on revenue growth of 39%. Inventories went to ₩277.6 billion from ₩205.3 billion. Selling into distant markets ties up more cash than selling in Korea did.
Take the half year together and the picture is less alarming. First-half operating cash flow was ₩268.3 billion against ₩103.3 billion of capex. The cash cycle is stretching, not breaking.
Jiaxing was announced with six production lines. Samyang has since raised it to eight, before the plant has made anything. When the factory is running, group capacity across five plants reaches roughly 3.52 billion units a year. Jiaxing's 840 million of that is about a quarter of the total, aimed at a single country.
China is the largest instant noodle market on earth and it is held by domestic incumbents who have been there for decades. It is also the market where Korean consumer companies have the worst track record. After the 2017 dispute over the THAAD missile-defence system, Chinese retaliation gutted Lotte's retail business there and it never recovered. Nothing says Buldak repeats that. But building your first overseas plant into that particular market, rather than into the one currently buying your product, is a choice that deserves to be named as a choice.
The strategic logic is not hard to reconstruct. Chinese tariffs and logistics make exporting from Korea expensive. Local production also gets around the shelf-life problem on long ocean routes. And Buldak already sells in China through imports, so this is scaling something that exists rather than starting cold.
What the disclosures do not give is a demand figure. There is no published Chinese volume today to compare 840 million units against. Until the company puts one out, the plant is capacity in search of a number.
Samyang paid ₩29.8 billion of dividends in 2025. Net income was ₩388.7 billion. That is a payout ratio of 7.7%, and it has been falling as profits rise. In 2022 the ratio was closer to 17%.
Against a market capitalisation of ₩10.7 trillion, ₩29.8 billion is a yield of under 0.3%. Retained earnings have reached ₩1,387.8 billion, which is about 90% of total equity. Essentially everything the business earns stays inside it.
There is a structural oddity underneath. Share capital has been ₩37.7 billion, unchanged, every year since 2015. Samyang has never split and never issued. There are 7,533,015 shares outstanding, and one of them costs ₩1,417,000. Korea's Value-Up campaign has spent two years pushing listed companies toward higher payouts and better share liquidity. Samyang has done neither, while compounding earnings faster than almost any company in the index.
The shares trade at roughly 22 times trailing earnings and near 6.9 times book. That is not a cheap multiple for a company retaining everything and spending it on plants that have not opened.
The bear reading above assumes capacity is a risk. For most of the last three years, capacity was the binding constraint on this company, not demand. Management was rationing shipments. Building ahead of that is what a growth company is supposed to do, and the 2025 capex is the reason 2026 revenue could reach ₩770.3 billion in a single quarter.
The China plant may also be defensive rather than offensive. If Buldak's Chinese sales are already meaningful through import channels, local production protects margin and removes a tariff exposure. That case is plausible. It just is not proven in anything the company has published.
Low payout has a defence too. A business earning these returns on incremental capital should retain. The counter is that Samyang has ₩630.6 billion of cash on top of the retention, which is more slack than the capex plan appears to need.
And the working capital build could simply be the ordinary cost of shipping further. Receivables at ₩256.4 billion equal about 30 days of sales. That is not a stressed number by any standard.
The Jiaxing plant opens in January 2027. The figure that settles most of this argument is the first utilisation or volume disclosure that follows, because it will be the first time anyone outside the company can size Chinese demand against 840 million units of capacity.
Before that, the cash flow statement is the honest scoreboard. Full-year 2026 capex against operating cash flow will show whether 2025's negative free cash flow was the trough or the pattern. And the dividend declared for 2026 will show whether a company earning close to ₩500 billion a year still thinks 7.7% is the right share for the people who own it.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.